Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study focused on baricitinib's effect on patients with severe alopecia areata, highlighting its efficacy for hair regrowth and its potential to improve health-related quality of life and psychological symptoms, as seen in two phase 3 trials.

This study found that combined intake of enzyme food and collagen was more effective than either alone in improving scalp hair properties in middle-aged women.

This study reported that a non-ablative fractional laser effectively improved visible hair growth and scalp appearance in both men and women with androgenetic alopecia, with a high success rate in identifying post-treatment improvements, and no adverse events were documented among the 132 patients evaluated.

This study demonstrated that several botanical extracts possess antioxidant properties, reducing oxidative stress and lipid oxidation in scalp treatments, with rosemary extract showing potential to improve scalp condition in a 4-week consumer trial.

This study found that subcutaneous testosterone therapy improved scalp hair growth in a majority of androgen-deficient women who previously reported hair thinning and did not report hair loss as a side effect.

In this 24-week study, oral supplementation with hydrolyzed low-molecular-weight porcine placental peptides significantly improved scalp elasticity, hair diameter, tensile strength, surface roughness, and luster compared to placebo, suggesting its potential as a nutritional intervention for age-related scalp and hair changes.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

In this study, patients with alopecia areata who experienced sustained hair regrowth while being treated with baricitinib showed improvements in health-related quality of life and reductions in anxiety and depression symptoms over 104 weeks, according to the BRAVE-AA phase III trials.

This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.

This study found a positive association between clinically meaningful scalp hair regrowth and improvements in patient-reported outcomes, such as satisfaction and reduced psychosocial burden.

In this study on adolescents with severe alopecia areata, baricitinib treatment showed effective scalp, eyebrow, and eyelash regrowth after 52 weeks, benefiting both responders and partial or non-responders, potentially reducing the psychosocial impact of the disease.

This study reports that patients with severe alopecia areata who experienced sustained scalp regrowth while receiving continuous baricitinib treatment showed improvements in health-related quality of life and reductions in anxiety and depression symptoms.

In this study, baricitinib was evaluated for its effectiveness in promoting concurrent regrowth of scalp hair, eyebrows, and eyelashes in patients with severe alopecia areata, showing clinically meaningful responses compared to placebo.

This abstract does not provide specific results or a conclusion; additional context is needed to interpret the data.

This study found that patients with severe alopecia areata who experienced meaningful scalp hair regrowth showed greater improvements in health-related quality of life and reduced anxiety and depression compared to those with no or minimal regrowth.

This case study reported significant clinical improvement in a 26-year-old male with dissecting cellulitis of the scalp after treatment with upadacitinib, suggesting that JAK inhibitors may be a promising option for refractory cases, where standard treatments have limited success.

In this study, a scalp care solution with 0.5% timosaponin B‐II from Anemarrhena asphodeloides significantly improved hair luster, reduced hair fall, enhanced scalp hydration, and decreased scalp redness over 28 days, suggesting benefits for scalp health and hair loss prevention.

This study describes a case where stopping infliximab and using oral minocycline with topical treatments effectively resolved alopecia and scalp psoriasis in a woman with Crohn's disease.

This study found that an ethanolic extract from the microalga Tetrathelmis tetrathele exhibited anti-inflammatory effects, promoted the proliferation of certain skin and hair cells, and inhibited 5α-reductase activity, suggesting its potential as a therapeutic agent for preventing alopecia and enhancing scalp health.

Silymarin improves hair follicle health better than vitamin C by boosting cell growth and reducing oxidative stress.

This randomized, double-blind, placebo-controlled study found that a supplement containing hydrolysed collagen and vitamin C (Absolute Collagen) improved skin, scalp, and hair over 12 weeks when taken daily or every other day.

This article discusses the increasing global popularity of scalp micropigmentation for creating the illusion of hair density in hair restoration but does not present new research findings.

This case report describes significant clinical improvement in a 36-year-old male with androgenetic alopecia and seborrheic dermatitis after one-year of individualized homeopathic treatment, resulting in stabilized hair fall, reduced dermatitis, and new hair growth.

This study found that using a low-level light therapy helmet device daily for 24 weeks improved hair density and thickness among participants, though it did not significantly impact sebum secretion or erythema index.

This study observed that excimer laser therapy led to subjective improvements in hair appearance for 60% of scarring alopecia patients and reduced symptoms like scalp pain, burning, and pruritus, indicating potential as an adjunctive treatment for inflammatory control and disease stabilization.

In this study, adults with severe alopecia areata experienced greater improvements in hair regrowth, health-related quality of life, and reduced anxiety and depression symptoms after 36 weeks of treatment with baricitinib compared to placebo.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.

This study reported that participants applying topical human platelet exosome extract serum experienced significant improvements in hair volume, density, scalp coverage, and overall hair health compared to a placebo, and no adverse effects were observed.